Abstract
581 Background: Most guidelines recommend bone mineral density (BMD) monitoring at 1-2 years of aromatase inhibitor (AI) therapy for women who do not need bisphosphonate therapy according to baseli...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
